No Data
No Data
Is Guangzhou Wondfo BiotechLtd (SZSE:300482) A Risky Investment?
Wanfu Biotech: Report for the third quarter of 2024
guangzhou wondfo biotech (300482.SZ) released its performance for the first three quarters, with a net income of 0.436 billion yuan, an increase of 9.04%.
Guangzhou Wondfo Biotech (300482.SZ) released its third-quarter report for 2024, with the company's revenue for the first three quarters reaching 2...
The Market Lifts Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) Shares 40% But It Can Do More
Guangzhou Wondfo Biotech (300482.SZ): The new coronavirus home testing (OTC) product has received pre-market notification from the USA FDA.
GeLongHui October 8th | guangzhou wondfo biotech (300482.SZ) announced that the company recently received a notification from the USA Food & Drug Administration (USA Food and Drug Administration, hereinafter referred to as "FDA"), notifying that guangzhou wondfo biotech's new coronavirus family test kit (OTC version) Wondfo 2019-nCoV Antigen Test (Lateral Flow Method) has received a US FDA 510(K) pre-market notification. The company's new coronavirus family test (OTC) kit.
Guangzhou Wondfo BiotechLtd (SZSE:300482) Will Be Hoping To Turn Its Returns On Capital Around
No Data
No Data